Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Phibro Animal Health (NASDAQ:PAHC) is the #1 top healthcare stock out of 1119 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Phibro Animal Health (NASDAQ:PAHC) is: Value: A, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: B.

Phibro Animal Health (NASDAQ:PAHC) has a Due Diligence Score of 45, which is 20 points higher than the healthcare sector average of 25. It passed 16 out of 38 due diligence checks and has strong fundamentals. Phibro Animal Health has seen its stock return 79.2% over the past year, overperforming other healthcare stocks by 132 percentage points.

Phibro Animal Health has an average 1 year price target of $27.67, a downside of -12.28% from Phibro Animal Health's current stock price of $31.54.

Phibro Animal Health stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Phibro Animal Health, 33.33% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a Hold, while 0% have issued a Sell rating, and 33.33% have issued a Strong Sell.

Enhabit (NYSE:EHAB) is the #2 top healthcare stock out of 1119 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Enhabit (NYSE:EHAB) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.

Enhabit (NYSE:EHAB) has a Due Diligence Score of 7, which is -18 points lower than the healthcare sector average of 25. Although this number is below the industry average, our proven quant model rates EHAB as a "A".It passed 2 out of 33 due diligence checks and has weak fundamentals. Enhabit has seen its stock lose -22.96% over the past year, overperforming other healthcare stocks by 29 percentage points.

Cumberland Pharmaceuticals (NASDAQ:CPIX) is the #3 top healthcare stock out of 1119 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Cumberland Pharmaceuticals (NASDAQ:CPIX) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: C, Financials: B, and AI: C.

Cumberland Pharmaceuticals (NASDAQ:CPIX) has a Due Diligence Score of 30, which is 5 points higher than the healthcare sector average of 25. It passed 9 out of 33 due diligence checks and has average fundamentals. Cumberland Pharmaceuticals has seen its stock return 132.88% over the past year, overperforming other healthcare stocks by 185 percentage points.

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 12.73%, which is 11 percentage points higher than the healthcare sector average of 1.98%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 32.4% indicates that its high dividend yield is sustainable for the long-term.

Cryo Cell International (NYSEMKT:CCEL) has an annual dividend yield of 8.42%, which is 6 percentage points higher than the healthcare sector average of 1.98%.

Cryo Cell International's dividend payout ratio of 5,000% indicates that its high dividend yield might not be sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 7.06%, which is 5 percentage points higher than the healthcare sector average of 1.98%. Spok Holdings's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 160.3% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.16% in the last day, and up 1.6% over the last week. Sonnet Biotherapeutics Holdings was the among the top gainers in the healthcare sector, gaining 86.46% yesterday.

Sonnet BioTherapeutics shares are trading higher after the company announced a newly formed entity through a business combination with Rorschach to launch a Crypto treasury reserve strategy.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Centene (NYSE:CNC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Centene has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Centene's stock has dropped -53.58% in the past year. It has underperformed other stocks in the healthcare sector by -1 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has dropped -5.74% in the past year. It has overperformed other stocks in the healthcare sector by 47 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 2.06% in the past year. It has overperformed other stocks in the healthcare sector by 54 percentage points.

50.78% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 46.73% over the next year.

4.77% of healthcare stocks have a Zen Rating of A (Strong Buy), 11.1% of healthcare stocks are rated B (Buy), 45.11% are rated C (Hold), 27.45% are rated D (Sell), and 11.58% are rated F (Strong Sell).